Lovastatin in Treating Patients At High Risk of Melanoma
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The use of lovastatin may slow disease progression in patients at high risk of melanoma. It
is not yet known whether lovastatin is more effective than a placebo in treating patients at
high risk of melanoma. This randomized phase II trial studies how well giving lovastatin or
placebo works in treating patients at high risk of melanoma.